113 results
6-K
EX-99.1
BLU
Bellus Health Inc
28 Jun 23
GSK completes acquisition of BELLUS Health
11:05am
, rib fractures, social withdrawal, and loss of sleep.3,4 There are no approved medicines for RCC in the US and EU.
About camlipixant
Camlipixant
6-K
EX-99.3
BLU
Bellus Health Inc
19 May 23
Current report (foreign)
5:27pm
NUMBER (BUSINESS HOURS))
(SOCIAL INSURANCE/SECURITY NUMBER)
¨ DELIVER FUNDS VIA WIRE* (COMPLETE BOX E)
* IF THIS NAME OR ADDRESS IS DIFFERENT FROM YOUR … ) (including a U.S. resident alien). The TIN for an individual United States citizen or resident is generally the individual’s social security number
6-K
EX-99.1
BLU
Bellus Health Inc
19 May 23
Current report (foreign)
5:27pm
is a frequent, yet often under-recognized, medical condition that has significant physical, social, and psychological consequences on one’s quality of life … is a frequent, yet often under-recognized, medical condition that has significant physical, social, and psychological consequences on one’s quality
6-K
EX-99.2
BLU
Bellus Health Inc
12 May 23
Condensed Consolidated Interim Financial Statements of
4:32pm
that their condition has a marked effect on their quality of life including sleep disruption, fatigue, urinary incontinence, and disruption of social … on their quality of life including sleep disruption, fatigue, urinary incontinence, and disruption of social interactions. Currently
6-K
EX-99.1
BLU
Bellus Health Inc
12 May 23
BELLUS Health Reports First Quarter 2023 Financial Results and Business Highlights
4:02pm
, medical condition that has significant physical, social, and psychological consequences on one’s quality of life. There are currently no approved treatments
6-K
EX-99.2
a55c74jfr3
27 Apr 23
Material Change Report
6:04am
6-K
EX-99.1
t04cp9x
18 Apr 23
GSK reaches agreement to acquire late-stage biopharmaceutical company BELLUS Health
6:02am
6-K
EX-99.1
acw3fta6sg8mu63jwgx
5 Apr 23
BELLUS Health Announces Positive Results from its Phase 1 Bioavailability Equivalence Study Evaluating
7:01am
6-K
EX-99.1
ir3f27u
29 Mar 23
Current report (foreign)
5:26pm
6-K
EX-99.1
5cr1cu
14 Nov 22
Condensed Consolidated Interim Financial Statements of
5:26pm
6-K
EX-99.2
sjjft9isse5e khrduhu
14 Nov 22
Condensed Consolidated Interim Financial Statements of
5:26pm
SUPPL
i0tiqh3y6mif 5dcj0
14 Nov 22
Supplemental materials (foreign)
5:25pm
6-K
EX-99.1
w5evfrdrz8qt2
14 Nov 22
BELLUS Health Reports Third Quarter 2022 Financial Results and Business Highlights
4:03pm
6-K
EX-99.1
1ryepsmi
10 Nov 22
BELLUS Health to Participate in Two Upcoming Healthcare Investor Conferences
4:01pm
6-K
EX-99.1
vw3pq 5i173
11 Oct 22
BELLUS Health to Present Clinical Data from Phase 2b SOOTHE Trial of BLU-5937 at the CHEST Annual Meeting
7:00am
6-K
EX-99.1
bwuch1e6
16 Sep 22
Investor Presentation NASDAQ/TSX - BLU September 16 th , 2022
4:40pm
6-K
EX-99.1
n483x5tz1ftfvt4
6 Sep 22
BELLUS Health to Present at the H.C. Wainwright Global Investment Conference
7:00am
F-10
q0zp7qlufuv52uv
26 Aug 22
Registration of securities (Canada)
4:48pm
6-K
EX-99.1
31v2a 3f2lxi9o078
22 Aug 22
Bellus Health Inc. 6-K
7:01am
6-K
EX-99.1
j05t3i8
10 Aug 22
Condensed Consolidated Interim Financial Statements of
4:56pm